Alterity Therapeutics has shown its Multiple System Atrophy drug ATH-434 has a potential market value of US$2.4 billion if approved. ... Read More The post StockTake: Alterity’s ATH434 shows US$2.4b ...
As they explained in their case report in the Journal of Neurology and Neuroscience, ophthalmologic examination identified ...
While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
On August 24, 2006, our solar system lost a planet. It wasn't by cataclysmic destruction, but rather by the vote of the International Astronomical Union, which declared that Pluto, considered the ...
Health Policy and Health Economics researcher and a Honorary Researcher at the Centre for Health Services Studies, University of Kent Ethiopia has built a national emergency medical team and hosts ...
All of the original US senators who created and sustained NASA's Space Launch System rocket over the last 15 years—Bill Nelson, Kay Bailey Hutchison, and Richard Shelby—have either retired or failed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback